Abstracts tagged "certolizumab pegol and psoriatic arthritis"

Abstract Number: 2860 • 2015 ACR/ARHP Annual Meeting
Clinical Responses in Joint and Skin Outcomes and Patient-Reported Outcomes Are Associated with Increased Productivity in the Workplace and at Home in Psoriatic Arthritis Patients Treated with Certolizumab Pegol
Arthur Kavanaugh¹, Dafna Gladman², Désirée van der Heijde³, Oana Purcaru⁴ and Philip J. Mease⁵, ¹University of California San Diego, La Jolla, CA, ²University of Toronto, Toronto, ON, Canada, ³Leiden University Medical Center, Leiden, Netherlands, ⁴UCB Pharma, Brussels, Belgium, ⁵Rheumatology Research, Swedish Medical Center, Seattle, WA
Background/Purpose: Compared to the general population, patients (pts) with psoriatic arthritis (PsA) suffer greater amounts of disability and substantially lower employment rates.1 Few studies have…
Abstract Number: 2613 • 2012 ACR/ARHP Annual Meeting
Effect of Certolizumab Pegol On Signs and Symptoms in Patients with Psoriatic Arthritis with and without Prior Anti-TNF Exposure: 24 Week Results of a Phase 3 Double-Blind Randomized Placebo-Controlled Study
Philip J. Mease¹, Roy Fleischmann², Jürgen Wollenhaupt³, Atul A. Deodhar⁴, Danuta Kielar⁵, Franz Woltering⁶, Christian Stach⁶, Bengt Hoepken⁶, Terri Arledge⁷ and Désirée van der Heijde⁸, ¹Seattle Rheumatology Associates, Seattle, WA, ²University of Texas Southwestern Medical Center at Dallas, Dallas, TX, ³Schön-Klinik, Hamburg, Germany, ⁴Oregon Health & Science University, Portland, OR, ⁵UCB Pharma, Brussels, Belgium, ⁶UCB Pharma, Monheim am Rheim, Germany, ⁷UCB Pharma, Rtp, NC, ⁸Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Certolizumab pegol (CZP), a PEGylated Fc-free anti-TNF, has shown efficacy in reducing signs and symptoms of psoriatic arthritis (PsA).1 RAPID-PsA (NCT01087788) is the first…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].